Skip to main content
. 2017 Jun 15;8:15804. doi: 10.1038/ncomms15804

Figure 3. In vitro reconstitution and characterization of XiaF and XiaP.

Figure 3

(a) Structures of substrates and products of XiaF enzyme assays. (b) HPLC-HRMS monitoring (PDA 300 nm) showing the results of (I) XiaF enzyme assays with indosespene (2) as the substrate in the presence and absence of XiaP (the asterisk denotes the proposed transient intermediate prexiamycin (8); for details, see Supplementary Fig. 6); (II) XiaF enzyme assays with indole (10) as the substrate in the presence and absence of XiaP. The profiles showing the reference compounds indosespene (2) and xiamycin (3) as well as indigo (11) and indirubin (12) are composed of different measurements of pure compounds (colour coded). (c) In vitro activity test of flavin reductase XiaP (0.1 μM). Conversion rates were followed by measuring the decrease in absorbance at 340 nm over time. Data represent mean values of three independent experiments, each conducted as duplicates. Error bars indicate s.d.